In8Bio (INAB) Enterprise Value (2020 - 2026)
In8Bio (INAB) posted Enterprise Value of -$21.9 million for Q1 2026, up 19.01% sequentially from -$27.1 million in Q4 2025, and down 84.56% YoY from -$142.1 million in Q1 2025.
In8Bio (INAB) Enterprise Value (2020 - 2026) Analysis & Trends
In8Bio has reported Enterprise Value for 7 years, with the latest figure at -$21.9 million in Q1 2026.
- Quarterly Enterprise Value fell 84.56% year-over-year to -$21.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.9 million (down 84.56% YoY) and the FY2025 annual result came in at -$27.1 million, down 137.94% from the prior year.
- Enterprise Value climbed to -$21.9 million in Q1 2026 per INAB's latest filing, from -$27.1 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$4.3 million in Q3 2024 and troughed at -$32.4 million in Q1 2022.
- A 5-year average of -$17.1 million and a median of -$13.5 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 66.86% in 2024, then tumbled 150.92% in 2025.
- Over 5 years, Enterprise Value stood at -$18.4 million in 2022, then slipped by 16.84% to -$21.5 million in 2023, then soared by 47.14% to -$11.4 million in 2024, then tumbled by 137.94% to -$27.1 million in 2025, then increased by 19.01% to -$21.9 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$21.9 million, -$27.1 million, and -$10.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 2.12 Bn |
| 10 | In8Bio | 23.75 Mn | 23.75 Mn | - | -18.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.13 Mn |
| Mar 31, 2026 | -21.94 Mn |
| Dec 31, 2025 | -27.09 Mn |
| Sep 30, 2025 | -10.69 Mn |
| Jun 30, 2025 | -13.50 Mn |
| Mar 31, 2025 | -11.89 Mn |
| Dec 31, 2024 | -11.39 Mn |
| Sep 30, 2024 | -4.26 Mn |
| Jun 30, 2024 | -10.48 Mn |
| Mar 31, 2024 | -13.02 Mn |
| Dec 31, 2023 | -21.54 Mn |
| Sep 30, 2023 | -12.85 Mn |
| Jun 30, 2023 | -16.99 Mn |
| Mar 31, 2023 | -10.86 Mn |
| Dec 31, 2022 | -18.43 Mn |
| Sep 30, 2022 | -27.90 Mn |
| Jun 30, 2022 | -25.99 Mn |
| Mar 31, 2022 | -32.36 Mn |
| Dec 31, 2021 | -37.27 Mn |
| Sep 30, 2021 | -40.68 Mn |